Amarantus Bioscience Holdings Inc (AMBS)

[MUKA1]

While it doesn't represent lock-tight connection about the specifics of a relationship between AMBS(MANF) and Banyan(who given that their website's "latest news" is from 2012 seems rather pathetic about keeping a stream of up-to-date developments) there certainly is enough reason to strongly speculate,

"MANF significantly inhibited caspase and calpain-mediated cellular processes of cell death and conferred overall neuroprotection in our cellular model systems of TBI," said Dr. Juan Martinez, Director of Scientific Operations at Banyan Biomarkers. "This neuroprotection indicates therapeutic potential based on well-defined biochemical pathway inhibition. We look forward to working with Amarantus to further develop MANF's therapeutic potential in TBI."
http://ir.stockpr.com/amarantus/company-news/detail/574/amarantus-bioscience-and-banyan-biomarkers-to-present-poster-of-manf-data-at-the-3rd-annual-traumatic-brain-injury-conference


"The data shows that MANF has a significant ability to reduce cell death from a variety of insults that simulate Traumatic Brain Injury as we have modeled in multiple assays in our internal laboratories at Banyan," said Dr. Andreas Jeromin, PhD, Senior Director Research at Banyan, "These data give us confidence to move to the next phase of testing to further validate this approach, as well as look at innovative product development strategies to accelerate bringing a MANF-based treatment to patients for TBI."
http://www.prnewswire.com/news-releases/amarantus-biosciences-and-banyan-biomarkers-announce-positive-data-from-traumatic-brain-injury-collaboration-157732095.html

Also given that these Banyan statements were been made within the time periods that we do know Banyan has been working with DOD on TBI including a verified study involving human patients.